ACP
IDXX icon

Ashfield Capital Partners’s Idexx Laboratories IDXX Stock Holding History

Ashfield Capital Partners’s Portfolio IDXX Stock Details IDXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-478
Closed -$261K – 235
2022
Q1 		$261K Hold
478
– – 0.02% 222
2021
Q4 		$315K Hold
478
– – 0.02% 215
2021
Q3 		$297K Sell
478
-53
-10% -$35.6K 0.02% 217
2021
Q2 		$335K Sell
531
-4
-0.7% -$2.21K 0.02% 210
2021
Q1 		$262K Hold
535
– – 0.02% 220
2020
Q4 		$267K Sell
535
-30
-5% -$13.4K 0.02% 214
2020
Q3 		$222K Buy
+565
New +$209K 0.02% 212

Other funds holding IDXX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Ashfield Capital Partners's IDXX Position: Q2 2022 in Review

Ashfield Capital Partners sold out of Idexx Laboratories (IDXX) in Q2 2022, closing a stake of 478 shares — an estimated $261K sold.

Ashfield Capital Partners first reported a position in IDXX in Q3 2020 and held it in 7 quarters. The position peaked at $335K in Q2 2021. 956 funds tracked by Wall St. Rank hold IDXX as of Q2 2022.

  • Ashfield Capital Partners reported no remaining Idexx Laboratories position as of Q2 2022 after selling out during the quarter.
  • Ashfield Capital Partners sold 478 Idexx Laboratories shares in Q2 2022, an estimated $261K.
  • Ashfield Capital Partners first reported a position in Idexx Laboratories in Q3 2020 and held it in 7 quarters.
  • Ashfield Capital Partners's Idexx Laboratories position peaked at $335K in Q2 2021.
  • 956 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2022.

Based on Ashfield Capital Partners's 13F filing for Q2 2022, filed 29 Jul 2022.